Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19

NCT ID: NCT05126511

Last Updated: 2023-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-19

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to investigate the effect of cranial electrotherapy stimulation (CES), for one hour a day over 3 weeks pulmonary rehabilitation (PR) program on symptoms of anxiety in post-Covid patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many patients recovering from Covid-19 develop sequelae related to the disease. In addition to lung issues, symptoms of Post-Covid/Long-Covid Syndrome include fatigue, brain fog, amyosthenia, insomnia, anxiety and depression. These symptoms play a major role in post-Covid patients recovery.

CES (Cranial electrotherapy stimulation) is a non-invasive therapy using low intensity alternating current applied through electrodes attached to the ear lobe.

CES has been used to improve the condition of non covid patients suffering from depression, anxiety, fatigue and cognitive disabilities. This is thought to be due to a change in electric waves of the brain with an increase of alpha-waves and a decrease of beta- and delta-waves, as well as a change of concentration of neurotransmitters, e.g. beta-endorphin or serotonin.

Therefore, this study aims to investigate the effect of CES in addition to normal PR, compared to PR alone on symptoms (e.g. anxiety) in post-Covid patients.

Hypothesis: Three weeks of PR including daily use of CES for one hour will have a positive effect on symptoms of anxiety.

Trial: 40 patients post-Covid reffered to inpatient PR will be recruited and allocated to one of two different groups. Group1: Anxious participants, Group 2: Non anxious participants. Within groups particpants will be randomized to intervention or control/sham. Intervention group will be using a functional device, and the other using a non-functional, SHAM device.

Anxiety is evaluated using the Beck anxiety inventory on admission and at discharge from PR.

Questionnaires to evaluate fatigue, depression and insomnia are the Fatigue Assessment Scale, PHQ-9, PSQI).

A diary will be kept by each participant with a log of general health and mood over the PR program.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

POST-Covid 19 Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Post-Covid patients, anxious, functional device

Applitation of 100µA CES for one hour per day to anxious patients

Group Type ACTIVE_COMPARATOR

Application of CES via ear clips

Intervention Type DEVICE

Use of 100µA CES for one hour per day over PR program

Post-Covid patients, anxious, Sham

Use of Sham CES for one hour per day by anxious patients

Group Type PLACEBO_COMPARATOR

Sham: No application of CES via ear clips

Intervention Type DEVICE

Use of Sham CES for one hour per day over PR programm

Post-Covid patients, non anxious, functional device

Application of 100µA CES for one hour per day to non anxious patients

Group Type ACTIVE_COMPARATOR

Application of CES via ear clips

Intervention Type DEVICE

Use of 100µA CES for one hour per day over PR program

Post-Covid patients, non anxious, Sham

Use of Sham CES for one hour per day by non anxious patients

Group Type PLACEBO_COMPARATOR

Sham: No application of CES via ear clips

Intervention Type DEVICE

Use of Sham CES for one hour per day over PR programm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Application of CES via ear clips

Use of 100µA CES for one hour per day over PR program

Intervention Type DEVICE

Sham: No application of CES via ear clips

Use of Sham CES for one hour per day over PR programm

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group with anxiety:

* high Beck Anxiety Inventory Score
* ≥18 years
* post SARS-CoV-2 infection
* written consent

Group without anxiety:

* low Beck Anxiety Inventory Score
* ≥18 years
* post SARS-CoV-2 infection
* written consent

Exclusion Criteria

* acitve implants (cardiac pacemaker,...)
* pregnancy, lactation period
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Schön Klinik Berchtesgadener Land

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Dr. Andreas Rembert Koczulla

Head of Pneumological Department Affiliation: Schön Klinik Berchtesgadener Land

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Klinikum Berchtesgadener Land, Schön Kliniken

Schönau am Königssee, Bavaria, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AlphaStim

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.